The Executive team has a proven track record in moving rapidly from scientific concepts to clinical development.

The achievement of our goals is largely driven by the competences and the skills of the ASIT biotech employees. Expertise, professional experience and commitment are at the heart of our business. It is through the dedicated work of ASIT biotech's teams that breakthrough allergy immunotherapy drugs are invented and further developed for commercialization.

Executive management team

Baijot 2018 13bff

Michel Baijot
CEO

Bioengineer, PhD, Michel Baijot is a life science executive bringing over 25 years of experience in building biologicals businesses with significant contribution in strategy, licensing, M&A and technology transfer.

His positions with biotech and big pharmaceutical companies as well as his tangible achievements reflect an in-depth knowledge of the business environment in both developed and emerging markets.

He is currently Board Director of IRE-Elit, the RadioPharma Division of IRE, and Board Director of OncoRadiomics. His previous positions include Executive Director Europe at Serum Institute of India, Head of Cipla Global Vaccine, Chief Business Officer at Janssen/Crucell, Vice President Worldwide Strategic Alliances and Business Development at GlaxoSmithKline Biologicals and Vice President Business Development at Innogenetics. He was Chairman of the Belgian Biotech Association during 5 years.

YvesDesiront

Yves Desiront
CFO

Yves Désiront is the Managing Partner of a private equity fund based in Luxembourg and is acting, since October 2014, as Group CFO under a consulting contract with BGP Investment, a Luxembourg real estate group based in Luxembourg. Previously he acted as Group CFO of Orco Property Group. Prior to this he served in various roles at Groupe Bruxelles Lambert and Générale de Banque. Yves Désiront obtained in 1994 a master degree as Ingénieur Commercial in Business Administration and Technology Interface from I.C.H.E.C. Brussels.

Philippe Ghem

Philippe Ghem
Chief Commercial Officer

Commercial Engineer from the Solvay Business School and holder of a license in Business and Marketing from HEC Saint Louis (now ICHEC, Brussels), Philippe Ghem brings over 20 years of commercial expertise in the pharmaceutical industry (retail, hospital, vaccines, devices) gained in sales and marketing positions of big pharma (ABBOTT, GSK, NOVARTIS) and specialty companies (COLOPLAST, GRUNENTHAL). In recent positions he was also regularly involved in Market Access and Business Development activities. Philippe Ghem joined ASIT Biotech in April 2018 as Chief Commercial Officer.

Vincent Bille

Vincent Bille
Vice-President CMC

Holder of a PhD in Biochemistry from the University of Namur and a Master in Business Administration (IAG) from the Catholic University of Louvain-La-Neuve, Vincent Bille started his career at UCB as Head of the Peptide Department within the contract manufacturing division and became Director Commercial Operations, North America and General Manager US. He was then Director Sales & Business Development for Lonza in the US and Europe. In 2007, he founded Marble Pharma Consult sprl which provides consultancy services in externalized development and manufacturing operations. Vincent Bille joined ASIT Biotech as Head of CMC in 2016 to manage the manufacturing of the ASIT products.

Sabine Pirotton

Sabine Pirotton
Head of Research and Development

Holder of a PhD in Biochemistry from the Free University of Brussels, Sabine Pirotton joined ASIT Biotech in 2005 after 20 years as a Senior Scientist at the University of Brussels and Namur. She is a co-inventor of most of the patents filed by ASIT biotech. Today, Sabine Pirotton is Head of Research and Development, and continues to explore new promising drug candidates with her dedicated team.

Gilles DELLA CORTE web

Gilles Della Corte
Chief Medical Officer

After ten years of hospital practice as physician in France, Dr. Gilles Della Corte joined the Pharmaceutical Industry in 1990, and worked in several Pharma Companies, Biotech and CROs (e.g. Rhone-Poulenc-Rorer, Servier, Solvay Pharma, Merck Serono, Omnicare Clinical Research, Therapharm). From 2013 to 2016 he was Clinical Development Director at Anergis, a start-up working in the field of allergy immunotherapy. In 2016, Gilles created his own Consulting Company named DellMed Consulting.  During this 28-year career he held various management positions, mainly in R&D from Phase I to Phase IV, but also Business oriented leading to a strong understanding of start-to-end product development process and registration. He joined ASIT biotech as Chief Medical Officer in October 2018.

Vincent Theunissen

Vincent Theunissen
Head of Human Resources

Graduate from the University of Louvain, Vincent Theunissen holds a Master’s degree in psychology. He started his career at Carrefour then joined IKEA in 2005 to manage the HR Department and participate to the opening of a new store in Arlon. In 2008, Vincent joined Premier Farnell European Distribution Center as Human Resources Manager Benelux. In 2010, he was appointed Senior Vice President Human Resources at EVS SA, a Belgian company providing broadcast solutions. Vincent Theunissen joined ASIT biotech in June 2017 as Head of Human Resources.

 Rem von Frenckell

Rémy von Frenckell
Head of Clinical Development

Civil Engineer in Chemistry and holder of a PhD in Experimental Biomedical Sciences, Remy von Frenckell has more than 35 years of experience in drug development in Academia (University of Liège) and in the pharmaceutical industry (BMS, UCB). He has more than 150 publications in peer reviewed journals. In his extensive career and after 15 years in Academia, he started in the pharmaceutical industry as Associate Director Biostatistics and Data Management at BMS, then joined UCB as Vice-President Statistics, Data Management, Outcomes Research, and finally EORTC (European Organization for Research and Treatment of Cancer) as Director Methodology & Operations. Remy von Frenckell joined ASIT Biotech in November 2016 as a consultant and is now Head of Clinical Development.